Mouse Anti-DLEU1 Recombinant Antibody (V2-32920) (CBMAB-D1021-YC)

Lv, T., Liu, H., Wu, Y., & Huang, W. (2021). Knockdown of lncRNA DLEU1 inhibits the tumorigenesis of oral squamous cell carcinoma via regulation of miR‑149‑5p/CDK6 axis. Molecular Medicine Reports, 23(6), 1-11.

Zhao, J. L., Zhao, L. L., Niu, W. Z., Ding, X. C., & Zhang, W. L. (2020). Deleted in lymphocytic leukemia 1 promoted proliferation and apoptosis of nephroblastoma cells through regulating miR-513a-5p and RANBP2 pathway. Zhonghua Zhong liu za zhi [Chinese Journal of Oncology], 42(10), 849-855.

Li, Z., & Hou, M. (2020). lncRNA deleted in lymphocytic leukaemia 1 (DLEU1) promotes the migration and invasion of human embryonic trophoblast cells. Zygote, 28(5), 397-402.

Zhang, W., Liu, S., Liu, K., & Liu, Y. (2019). Long non‐coding RNA deleted in lymphocytic leukaemia 1 promotes hepatocellular carcinoma progression by sponging miR‐133a to regulate IGF‐1R expression. Journal of Cellular and Molecular Medicine, 23(8), 5154-5164.

Gao, S., Cai, Y., Zhang, H., Hu, F., Hou, L., & Xu, Q. (2019). Long noncoding RNA DLEU1 aggravates pancreatic ductal adenocarcinoma carcinogenesis via the miR‐381/CXCR4 axis. Journal of cellular physiology, 234(5), 6746-6757.

Feng, L., He, M., Rao, M., Diao, J., & Zhu, Y. (2019). Long noncoding RNA DLEU1 aggravates glioma progression via the miR-421/MEF2D axis. OncoTargets and therapy, 12, 5405.

Yue, G., Chen, C., Bai, L., Wang, G., Huang, Y., Wang, Y., ... & Xiao, Y. (2019). Knockdown of long noncoding RNA DLEU1 suppresses the progression of renal cell carcinoma by downregulating the Akt pathway. Molecular Medicine Reports, 20(5), 4551-4557.

Nishiyama, K., Maruyama, R., Niinuma, T., Kai, M., Kitajima, H., Toyota, M., ... & Suzuki, H. (2018). Screening for long noncoding RNAs associated with oral squamous cell carcinoma reveals the potentially oncogenic actions of DLEU1. Cell death & disease, 9(8), 1-12.

Lee, S., Luo, W., Shah, T., Yin, C., O’Connell, T., Chung, T. H., ... & Cairo, M. S. (2017). The effects of DLEU1 gene expression in Burkitt lymphoma (BL): potential mechanism of chemoimmunotherapy resistance in BL. Oncotarget, 8(17), 27839.

Please try the standard protocols which include: protocols, troubleshooting and guide.

Enzyme-linked Immunosorbent Assay (ELISA)
Flow Cytometry
Immunofluorescence (IF)
Immunohistochemistry (IHC)
Immunoprecipitation (IP)
Western Blot (WB)
Enzyme Linked Immunospot (ELISpot)
Proteogenomic
Other Protocols